At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 294 enrolled
Drug / intervention
Deferoxamine Mesylate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Deferoxamine Mesylate in Intracerebral Hemorrhage
In Brief
A Phase 2 clinical trial evaluating Deferoxamine Mesylate and Placebo (for Deferoxamine Mesylate) for Intracerebral Hemorrhage. Completed, enrolled 294 participants across 28 sites in 2 countries.
Detailed Summary
The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage. The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntracerebral Hemorrhage
CountriesCanada, United States
CollaboratorsMedical University of South Carolina, National Institute of Neurological Disorders and Stroke (NINDS), Massachusetts General Hospital, University of Massachusetts, Worcester, University of Pennsylvania, Johns Hopkins University, Duke University, University of North Carolina, University of Florida, Henry Ford Hospital, Ohio State University, St. Joseph's Hospital and Medical Center, Phoenix, University of California, San Francisco, Oregon Health and Science University, Yale New Haven Health System Center for Healthcare Solutions, University of Iowa, Hartford Hospital, The University of Texas Health Science Center, Houston, Rhode Island Hospital, Stanford University, University of Washington, University of Calgary, Hopital de l'Enfant-Jesus, University of Alberta, Rush University Medical Center, University Hospitals Cleveland Medical Center, Columbia University, Weill Medical College of Cornell University, NYU Langone Health, Mount Sinai Hospital, New York, Loyola University
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartOct 2014
Primary CompletionFeb 2018
Study CompletionMay 2018
TodayJul 2026
First PostedJun 26, 2014
Enrollment StartOct 1, 2014
Primary CompletionFeb 10, 2018
Study CompletionMay 30, 2018
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 12.0 years ago
Interventions
Deferoxamine Mesylatedrug
Placebo (for Deferoxamine Mesylate)drug